Details

Autor(en) / Beteiligte

• Bel, Elisabeth H
• Wenzel, Sally E
• Thompson, Philip J
• Prazma, Charlene M
• Keene, Oliver N
• Yancey, Steven W
• Ortega, Hector G
• Pavord, Ian D

Titel

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

Ist Teil von

• The New England journal of medicine, 2014-09, Vol.371 (13), p.1189-1197

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Among patients with asthma who had elevated blood eosinophil levels and marginal asthma control despite glucocorticoid treatment, the glucocorticoid dose could be significantly reduced in patients receiving a monoclonal antibody that binds to and inactivates interleukin-5. Asthma is a common chronic inflammatory disease of the airways that affects 5 to 10% of adults and children. Although the disease is well controlled with inhaled therapy in most patients, approximately 10% have severe asthma that is associated with substantial morbidity, mortality, and economic effects. 1 Patients with severe asthma have complex treatment requirements, which in 30 to 40% of such patients include the regular use of oral glucocorticoids to control their asthma. 2 – 4 Such therapy can result in serious and often irreversible adverse effects. 5 , 6 Current treatments with glucocorticoid-sparing properties are not recommended in patients with severe asthma because . . .